Session » Sjögren's Syndrome – Basic & Clinical Science Poster I

Date: Sunday, November 17, 2024

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2024

10:30AM-12:30PM: Abstract Number: 1428

A Post-hoc Analysis of Two Phase 2 Randomized Controlled Trials in Patients with Active Sjogren’s Disease Exploring the Novel Composite Endpoint Sjögren’s Tool for Assessing Response (STAR)

10:30AM-12:30PM: Abstract Number: 1420

Alignment Between Rheumatology and Neurology of Nomenclature for Peripheral Nervous System Neuropathies

10:30AM-12:30PM: Abstract Number: 1423

An Observational Analytical Study on HCV Patients with Sicca Manifestations Before and After Direct-Acting Antivirals in Comparison with Sjogren’s Disease; Infection versus Autoimmunity

10:30AM-12:30PM: Abstract Number: 1419

Antiphospholipid Antibodies and Hypercoagulable Events in Patients with Sjogren’s Syndrome

10:30AM-12:30PM: Abstract Number: 1429

Association of Bone Erosion and Microarchitecture with Disease Activity and Damage in Sjögren’s Disease

10:30AM-12:30PM: Abstract Number: 1424

Associations of Human Leukocyte Antigens (HLA) Class II with Interstitial Lung Disease (ILD) in Patients with Systemic Autoimmune Rheumatic Diseases (SARDs). A Prospective Study in Sequential Patients with SARD-ILD

10:30AM-12:30PM: Abstract Number: 1430

C57BL/6.NOD-Aec1Aec2 Mice Recapitulate Sjögren’s Serology Better Than NOD.B10Sn-H2b Models and JAK Inhibitor Treatment Improves Immunoglobulins and Salivary Gland Inflammation but Not Salivary Flow in Sjögren’s Mice

10:30AM-12:30PM: Abstract Number: 1408

Color Doppler Ultrasound Is a Reliable Method for Imaging the Lacrimal Glands in Patients with Suspected Sjögren’s Disease

10:30AM-12:30PM: Abstract Number: 1431

Computational Systems Biology Approach to Unveil Molecular Interactions in Sjogren’s Disease Pathogenesis

10:30AM-12:30PM: Abstract Number: 1406

Development and Functional Characterization of Salivary Gland Organoids to Investigate Sjögren’s Disease

10:30AM-12:30PM: Abstract Number: 1432

Diagnostic Performance of Mayor Salivary Gland Ultrasound for Diagnosis of Sjögren’s Syndrome in Routine Clinical Practice

10:30AM-12:30PM: Abstract Number: 1421

Differential Impact of B-cell Targeted Monotherapy and Combination Regimen on the Peripheral Blood Transcriptome of Adults with Active Sjögren Disease

10:30AM-12:30PM: Abstract Number: 1422

Evaluation of Salivary Gland Focus Score in Sjogren’s Disease Using Deep Learning: A Step Towards Tissue Biomarker Discovery

10:30AM-12:30PM: Abstract Number: 1414

Evidence-Based Guidelines for Sjögren’s Disease Peripheral Nervous System Manifestations

10:30AM-12:30PM: Abstract Number: 1411

Impact of Patient and Physician Alignment on Sjögren’s Disease Severity, a Real-World Survey on Patients’ Clinical Outcomes and Health-Related Quality of Life

10:30AM-12:30PM: Abstract Number: 1415

Metformin Improves Salivary Gland Infiltration and Objective Measures of Dry Eyes in Sjögren’s Disease: A Retrospective Observational Study

10:30AM-12:30PM: Abstract Number: 1427

Observed and Simulated Pharmacokinetics and Pharmacodynamics of Nipocalimab, a Fully Human FcRn Blocking Monoclonal Antibody, in Adults with Sjögren’s Disease: Results from a Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study

10:30AM-12:30PM: Abstract Number: 1417

Organ-Specific Autoimmune Involvement in Primary Sjögren’s Disease

10:30AM-12:30PM: Abstract Number: 1413

Pilot Trial of Ustekinumab for Primary Sjogren’s Syndrome

10:30AM-12:30PM: Abstract Number: 1409

Salivary Organoids Contain More Diverse Epithelial and Less Mesenchymal Cells Than Adherent Cultures: Choose Your Sjögren’s Disease Research Tool Carefully

10:30AM-12:30PM: Abstract Number: 1426

Single Cell RNA-Seq Characterization of Circulating Immune Cells in Sjogren’s Syndrome: Comparison to SLE and Rheumatoid Arhtritis

10:30AM-12:30PM: Abstract Number: 1425

Sjögren’s Syndrome and Interstitial Lung Disease: Experience in a Collaborative Rheumatology-Pulmonology Clinic

10:30AM-12:30PM: Abstract Number: 1418

Soluble Immune Checkpoint Molecules as Biomarkers for Extraglandular Sjögren’s Disease

10:30AM-12:30PM: Abstract Number: 1412

Survival and Predictive Markers of Prognosis in Patients with Cancer Occurrence After Sjögren Syndrome: A Long-term Observational Study

10:30AM-12:30PM: Abstract Number: 1416

Ultrasound (US)-guided Core-needle Biopsy (CNB) of the Non-swollen Parotid Gland: A Feasible and Well-tolerated Technique for Diagnosing and Stratifying Sjögren’s Disease (SjD)

10:30AM-12:30PM: Abstract Number: 1410

Using Social Listening to Understand the Patient Voice: The Daily Impacts of Sjögren’s Disease

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].